Head-to-head · WeighScore
Boston Medical Group vs Roboclinic
The verdict
Roboclinic takes it — 65.3/100 to 61.9/100.
Roboclinic grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Roboclinic is an AI-first telehealth platform, operated by BrickFi, Inc., that starts you with an AI health assistant and then routes you to a board-certified provider for GLP-1 weight-loss care.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Boston Medical Group | Roboclinic |
|---|---|---|
| WeighScore | 61.9/100 | 65.3/100 |
| Grade | C | C |
| Scorecard rank | #279 | #223 |
| Semaglutide | $199/mo (starting strength, rising with dose, compounded) | $179/mo (12-month plan, compounded) |
| Tirzepatide | Not disclosed | $299/mo (12-month plan, compounded) |
| Coverage | 7 states | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Yes |
Graded #279 · C
Strengths
- An established medical group with a defined 12-week programme rather than an open-ended subscription
- The price range and the 12-week total are both published, once you reach the costs page
- Semaglutide is prescribed and dispensed under a compounded pathway with clinician oversight
Where it loses points
- The published rate is a range by dose strength, $199 to $299, so the figure quoted is the floor rather than what a titrated patient pays
- The 12-week programme totals $699 including a telemedicine platform fee that is never itemised — about $233/mo all-in, not $199
- The weight-loss landing page carries no price at all; the numbers are two pages deeper, in the FAQ and the costs page
- Semaglutide and tirzepatide are not priced separately — one range covers the whole programme
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Graded #223 · C
Strengths
- Compounded semaglutide from $179/mo and tirzepatide from $299/mo on 12-month plans
- One all-in price bundles the provider consult, prescription, and delivery
- Offers both injectable and oral (tablet) compounded semaglutide
- 'Same price, every dose' means your cost does not rise as the dose increases
- AI-first intake with board-certified provider review; no insurance necessary
Where it loses points
- Lowest rates require a 12-month plan; month-to-month runs $299/mo (semaglutide) to $399/mo (tirzepatide)
- Individual compounding pharmacies are not named; fulfillment is routed through OpenLoop Health
- No published per-state list; site claims 'all 50 states, restrictions apply' and gates doctor review by region
- Refunds limited to your most recent billing cycle; none for used or partially used periods
- Operated by BrickFi, Inc., a newer brand with limited independent track record
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.